Thierry Poynard, MD, PhD; Mona Munteanu, MD; Vlad Ratziu, MD; Yves Benhamou, MD, PhD; Vincent Di Martino, MD; Julien Taieb, MD; Pierre Opolon, MD
Acknowledgment: The authors thank Solko Schalm, MD, for his support and helpful comments.
Grant Support: By the European Association for Study of the Liver and Association pour la Recherche sur Maladies Hépatiques Virales.
Requests for Single Reprints: Thierry Poynard, MD, PhD, Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France; e-mail, email@example.com.
Current author addresses: Drs. Poynard, Munteanu, Ratziu, Benhamou, Di Martino, Taieb, and Opolon: Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
Poynard T, Munteanu M, Ratziu V, Benhamou Y, Martino VD, Taieb J, et al. Truth Survival in Clinical Research: An Evidence-Based Requiem?. Ann Intern Med. 2002;136:888-895. doi: 10.7326/0003-4819-136-12-200206180-00010
Download citation file:
Published: Ann Intern Med. 2002;136(12):888-895.
Factors associated with the survival of truth of clinical conclusions in the medical literature are unknown. The authors hypothesized that conclusions derived from studies using better methodology should have a longer half-life.
MEDLINE and hand searches of journals with studies on cirrhosis and hepatitis.
Original articles and meta-analyses published from 1945 to 1999 about cirrhosis or hepatitis in adults.
In 2000, 285 of 474 conclusions (60%) were still considered to be true, 91 (19%) were considered to be obsolete, and 98 (21%) were considered to be false. The half-life of truth was 45 years. The 20-year survival of conclusions derived from meta-analysis was lower (57% Â± 10%) than that from nonrandomized studies (87% Â± 2%) (P < 0.001) or randomized trials (85% Â± 3%) (P < 0.001). The survival of conclusions was not different when studies of high methodologic quality were compared with those of low quality. In randomized trials, the 50-year survival rate was higher for 52 negative conclusions (68% Â± 13%) than for 118 positive conclusions (14% Â± 4%) (P < 0.001).
Contrary to the authors' hypothesis, conclusions based on recognized, good methodology had no clear survival advantage. To better convince clinicians of the long-term utility of evidence-based medicine, better prognostic factors should be developed.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Liver Disease, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only